Who Exports Streptomycin from India — 57 Suppliers Behind a $573.8K Market
India's streptomycin export market is supplied by 57 active exporters who collectively shipped $573.8K across 150 shipments. LABORATE PHARMACEUTICALS INDIA LTD leads with a 22.2% market share, followed by ASHISH LIFE SCIENCE PRIVATE LIMITED and MACLEODS PHARMACEUTICALS LTD. The top 5 suppliers together control 62.8% of total export value, reflecting a concentrated market structure.
Top Streptomycin Exporters from India — Ranked by Export Value
LABORATE PHARMACEUTICALS INDIA LTD is the leading streptomycin exporter from India, holding a 22.2% share of the $573.8K market across 150 shipments from 57 exporters. The top 5 suppliers — LABORATE PHARMACEUTICALS INDIA LTD, ASHISH LIFE SCIENCE PRIVATE LIMITED, MACLEODS PHARMACEUTICALS LTD, SWISS PARENTERALS LIMITED, EVOLET HEALTHCARE PRIVATE LIMITED — collectively control 62.8% of total export value, indicating a moderately concentrated market. Individual shares are: LABORATE PHARMACEUTICALS INDIA LTD (22.2%), ASHISH LIFE SCIENCE PRIVATE LIMITED (16.1%), MACLEODS PHARMACEUTICALS LTD (10.3%), SWISS PARENTERALS LIMITED (8.2%), EVOLET HEALTHCARE PRIVATE LIMITED (6.0%).
Top Streptomycin Exporters from India
Ranked by export value · 57 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | LABORATE PHARMACEUTICALS INDIA LTD 1-251 REPTOCIN-5 INJECTION (STREPTOMYCIN1-83 REPTOCIN-5 INJECTION (STREPTOMYCIN | $127.3K | 1 | 22.2% |
| 2 | ASHISH LIFE SCIENCE PRIVATE LIMITED VET:ASHTRICIN TABLETSDEEC 0311014017DT:20-04PHARMACEUTICAL PRODUCTS 4)SIMO STREPT INJAMBISTRYN-S 1G INJ. STREPTOMYCIN INJECTION I.P. 1G | $92.5K | 1 | 16.1% |
| 3 | MACLEODS PHARMACEUTICALS LTD STERILE STREPTOMYCIN SULPHATE FOR INJECTSTREPTOMYCIN INJECTION IP 1GAMBISTRYN-S STREPTOMYCIN/1GM (5000 VIALS | $59.0K | 1 | 10.3% |
| 4 | SWISS PARENTERALS LIMITED | $46.8K | 1 | 8.2% |
| 5 | EVOLET HEALTHCARE PRIVATE LIMITED STREPTOMYCIN VIAL 1 G/5 ML #25 | $34.6K | 1 | 6.0% |
| 6 | ZENEX ANIMAL HEALTH INDIA PRIVATE LIMITED | $34.1K | 2 | 5.9% |
| 7 | AMARI TRADE ALLIANCE LLP MEDICINE FOR HUMAN USE STREPTOMYCIN INJAMBISTRYN S 1GM INJ VIAL STREPTOMYCININJECTIONAMBISTRYN S 1GM INJ (STREPTOMYCIN | $3.3K | 1 | 0.6% |
| 8 | M T MADON EXPORTS STERILE STREPTOMYCIN SULPHATE FOR INJECT1-251 REPTOCIN-5 INJECTION (STREPTOMYCINVET:ASHTRICIN TABLETSDEEC 0311014017DT:20-04 | $2.9K | 1 | 0.5% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Streptomycin exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| LABORATE PHARMACEUTICALS INDIA LTD | Not Listed | Yes (as of September | Yes (as of Augu | Not verified | EU-GMP certification granted to manufacturing site in Paonta Sahib, Himachal Pra |
| ASHISH LIFE SCIENCE PRIVATE LIMITED | Not Listed | Yes (date not specif | Yes (date not s | Not verified | WHO-GMP and EU-GMP certifications confirmed; specific dates not provided. (ashis |
| MACLEODS PHARMACEUTICALS LTD | Not Listed | Yes (as of September | Yes (as of June | Not verified | WHO-GMP certification for Sarigam facility; EU-GMP certification for Sarigam fac |
| SWISS PARENTERALS LIMITED | Not Listed | Yes (as of September | Not Listed | Not verified | WHO-GMP certification for Hajipur facility. |
TransData Nexus reviewed the regulatory standing of 4 leading Streptomycin exporters from India. 0 hold US FDA facility approvals, 4 maintain WHO-GMP certification, and 3 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Streptomycin sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is renowned for its extensive production of active pharmaceutical ingredients (APIs). The city hosts Genome Valley, India's first biotech cluster, and is home to over 800 pharmaceutical companies, including major players like Dr. Reddy’s Laboratories and Aurobindo Pharma. This concentration of expertise and infrastructure makes Hyderabad a significant hub for the manufacturing of APIs, which are essential for producing antibiotics such as Streptomycin.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is a major center for pharmaceutical formulations. Gujarat contributes nearly 28% of India's pharmaceutical production and houses leading companies like Cadila Pharmaceuticals and Torrent Pharmaceuticals. The region's robust infrastructure and regulatory compliance make it a key player in the production of finished pharmaceutical products, including injectable antibiotics like Streptomycin.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a crucial export gateway for India's pharmaceutical industry. Mumbai, being the financial capital, provides access to international markets and regulatory bodies. The region's well-established logistics and proximity to major ports facilitate the export of pharmaceutical products, including antibiotics, to various countries. Companies in this cluster benefit from the strategic location to distribute products like Streptomycin efficiently.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi, located in Himachal Pradesh, has emerged as a prominent pharmaceutical manufacturing hub, housing over 1,000 pharma units. The region's growth was significantly influenced by tax incentives and government policies that attracted numerous companies. Baddi's infrastructure supports large-scale production of various pharmaceutical products, including antibiotics. However, it's important to note that some of the initial tax benefits have been phased out, yet the established ecosystem continues to thrive.
5Sourcing Recommendations
- Diversify Supplier Base: Engage with multiple suppliers across different clusters to mitigate risks associated with regional disruptions.
- Evaluate Supplier Capabilities: Assess the technical expertise and production capacities of suppliers, especially those in Hyderabad for APIs and Ahmedabad-Vadodara for formulations.
- Leverage Export Infrastructure: Utilize the logistical advantages of the Mumbai-Thane-Raigad region to streamline international shipments.
- Monitor Regulatory Compliance: Ensure that suppliers adhere to international quality standards and regulatory requirements to maintain product integrity and market access.
By strategically sourcing from these specialized clusters, TransData Nexus can optimize its supply chain for Streptomycin, ensuring quality, efficiency, and reliability in meeting global demand.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Streptomycin exporters from India
Swiss Parenterals Limited — Eris Lifesciences acquires Swiss Parenterals Limited
Eris Lifesciences Limited completed the acquisition of Swiss Parenterals Limited on February 13, 2024. - IMPACT: This acquisition may lead to increased production capacity and expanded market reach for Streptomycin exports.
Impact: This acquisition may lead to increased production capacity and expanded market reach for Streptomycin exports.
Macleods Pharmaceuticals Ltd — Macleods Pharmaceuticals files Draft Red Herring Prospectus
Macleods Pharmaceuticals Limited filed a Draft Red Herring Prospectus on May 24, 2025, indicating plans for an initial public offering. - IMPACT: The IPO could provide additional capital for expanding Streptomycin production and export capabilities.
Impact: The IPO could provide additional capital for expanding Streptomycin production and export capabilities.
Swiss Parenterals Limited — Eris Lifesciences acquires remaining 30% stake in Swiss Parenterals
Eris Lifesciences Limited announced the acquisition of the remaining 30% stake in Swiss Parenterals Limited on November 24, 2025, making it a wholly-owned subsidiary. - IMPACT: Full ownership may streamline operations and enhance Streptomycin export efficiency.
Impact: Full ownership may streamline operations and enhance Streptomycin export efficiency.
Common Questions — Streptomycin Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which streptomycin supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, LABORATE PHARMACEUTICALS INDIA LTD leads with 4 recorded shipments worth $127.3K. ASHISH LIFE SCIENCE PRIVATE LIMITED (3 shipments) and MACLEODS PHARMACEUTICALS LTD (5 shipments) are also established high-volume exporters.
Q How many streptomycin manufacturers are there in India?
India has 57 active streptomycin exporters with a combined export market of $573.8K across 150 shipments to 36 countries. The top 5 suppliers hold 62.8% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for streptomycin from India?
Average FOB unit price: $6.24 per unit, ranging from $0.01 to $259.34. Average shipment value: $3.8K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 57 verified Indian exporters of Streptomycin ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 150 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 36 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
150 Verified Shipments
57 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists